億帆醫藥(002019.SZ):擬繼續使用不超5億元閒置募資進行現金管理
格隆匯4月12日丨億帆醫藥(002019.SZ)公佈,公司於2022年4月11日召開第七屆董事會第二十三會議、第七屆監事會第二十二次會議,審議通過了《關於繼續使用部分閒置募集資金進行現金管理的議案》,在保證募集資金投資項目正常實施及募集資金安全的前提下,同意公司繼續使用不超過5.0億元(含投資的收益進行再投資的相關金額)暫時閒置募集資金進行現金管理,投資於安全性高、流動性好、短期(不超過十二個月)的銀行保本型理財產品,期限自本次董事會審議通過之日起十二個月內有效,在上述額度和期限範圍內資金可滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.